ReseaRch aRticle
Human pharmacogenomic variation of antihypertensive drugs: from population genetics to personalized medicine Arterial hypertension is a major risk factor for many disorders (i.e., coronary artery disease, myocardial infarction, heart failure, stroke and renal failure), and drug therapy can effectively prevent these risks [1] . As demonstrated by molecular studies and family history, genetic variation affects both predisposition to the dis ease and drug response [2] . Several pharmaco logical medications are available for its treat ment, but hypertensionassociated diseases remain one of the main burdens of healthcare [3] . Furthermore, the prevalence of the disease is steadily growing. In 2025, it is estimated that 1.56 billion adults worldwide will have been diagnosed with hypertension [4] . Accordingly, hypertension has the highest rate of recurrent drug therapy [5] . Moreover, less than 50% of hypertension patients manage to control their blood pressure. Current therapy strategies in the general hypertensive population have not shown the same effectiveness as was observed in clinical trials [6] . These data suggest that the optimal investigative approach to produce the best antihypertensive therapies has not yet been established, and relevant enhancements in this field must be made in order to improve patient care and treatment efficacy. Indeed, the con trol of the economic cost related to the manage ment of hypertension and its adverse sequalae is an important objective for all national health systems [7] . In particular, relevant improve ments should be made to the selection crite ria of antihypertensive drugs and their related dosages. The study of genetic predisposition to drug response -pharmacogenomics -may produce useful tools to predict the most effec tive anti hypertensive drug for a patient prior to the initiation of therapy. In recent years, the number of studies on the pharmacogenetics of antihypertensive drugs has rapidly increased, and several genetic variants were found to be associated with the response of different antihypertensive drugs [8, 9] . Unfortunately, although hypertension pharmacogenetic data promises to play an important role in patient management, this information is not yet ready to be transferred from the bench to the bed side. Indeed, several confounding factors are present in the correlation between genotype (i.e., genomic background) and phenotype (i.e., response to antihypertensive drugs), such as environment and epigenetics [10] . This leads us to believe that multiple rare variants deter mine a great portion of the complex phenotype predisposition, shifting the attention from common genetic variants to rare ones [11] . This assumption strongly suggests that multiple rare variants with a high functional impact may Aim: To investigate the human pharmacogenetic variation related to antihypertensive drugs, providing a survey of functional interpopulation differences in hypertension pharmacogenes. Materials & methods:
The study was divided into two stages. In the first stage, we analyzed 1249 variants located in 57 hypertension pharmacogenes. This first-stage ana lysis confirmed that geographic origin strongly affects hypertension pharmacogenomic variation and that 31 pharmacogenes are geographically differentiated. In the second stage, we focused our attention on the ethnic-differentiated pharmacogenes, investigating 55,521 genetic variants. In silico analyses were performed to predict the effect of genetic variation. Results: Our analyses indicated functional interpopulation differences, suggesting insight into the mechanisms of antihypertensive drug response. Moreover, our data suggested that rare variants mainly determine the functionality of genes related to antihypertensive drugs. Conclusion: Our study provided important knowledge about the genetics of the antihypertensive drug response, suggesting that next-generation sequencing technologies may develop reliable pharmacogenetic tests for antihypertensive drugs.
future science group play a key role in pharmacogenomic research developments. To date, most of the hyperten sion pharmaco genomic studies conducted have been genecandidate investigations or genome wide association studies [10] . These approaches are not suitable for identifying rare variants, as they likely result in missing heritability in the genetic predisposition to antihypertensive drug response. The application of highthroughput and nextgeneration sequencing (NGS) tech nologies, coupled with bioinformatic ana lysis to predict the functional impact of genomic varia tion, may result in a useful approach that could help us investigate the genomic architecture of complex phenotypes, such as drug response [12, 13] . An interesting field, on which this ana lysis may provide remarkable information, is populationrelated investigation. Indeed, a number of studies have suggested that geo graphic origin is a relevant influencing factor in antihypertensive drug response and that geo graphic differences have also been observed in pharmacogenomic studies [14, 15] . Furthermore, there are public genomic databases of interna tional projects, such as the HapMap Project, the Human Genome Diversity Project (HGDP), and the 1000 Genomes Project, which provide a great deal of information on human genetic variation. This information is regularly used by researchers to investigate the relationships between geographic origin, genome variabil ity and health [16] [17] [18] . Using these public data, we performed an in silico ana lysis of human pharmaco genomic variation in relation to anti hypertensive drug response. Population genet ics are coupled with a functional prediction ana lysis that may result in new knowledge on hypertension pharmacogenomics, uncovering a portion of the genetic mechanisms of antihy pertensive drug response.
The aim of the present study was to provide a survey of functional geographic differences in hypertension pharmacogenes in order to under stand the genetic basis of geographic differences in antihypertensive drug response, and to obtain useful insights that could help move hypertension care into the 'personalized medicine' era. n Population information & genomic data Data were obtained from the HGDP and the 1000 Genomes Project, which provides infor mation on human genetic variation [16, 18] . In the first stage of the study, we considered 57 pharmacogenes that we identified using a lit erature search, and we made use of the genetic information available from the HGDP. In par ticular, information about 1249 SNPs analyzed in 1043 individuals belonging to 51 human populations within seven different geographi cal origins was used [101] . The definition of the HGDP population structure is based on seven geographic origin groups: Africa, Europe, Mid dle East, central Asia, east Asia, America and Oceania. Further details can be found in our previous study [19] . In the second stage, phase 1 of the 1000 Genomes Project was used to obtain genotypic data and haplotypic information [102] . Details pertaining to the 1000 Genomes populations are available at [103] . In this stage, a restricted number of pharmacogenes were considered on the basis of the firststage ana lysis. The total number of the pharmacogenes and of the considered variants is 31 and 55,521, respectively. n Functional prediction ana lysis The impact of single variants and of haplotypes on gene function was evaluated with various in silico tools and with a previously published algorithm. Details of the ana lysis were described in an earlier study [20] . This approach permits the distinguishing of functional haplotypes (i.e., haplotypecontaining genetic variants asso ciated with normal gene function) from non functional haplotypes (i.e., haplotypecontain ing genetic variants associated with abnormal gene function).
Materials & methods
To identify potential gene-gene interactions, the following databases were used: PharmGKB (available at [104] ) [21] [24] . n Statistical ana lysis Analyses of molecular variance and Fstatistics tests were performed by Arlequin 3.5.1.3 (Uni versity of Bern, Bern, Switzerland) [25] . The Fstatistics test was carried out by accounting for a hierarchical island model [26] . The calculation settings were: 50,000 simulations, 100 demes to simulate and ten groups to simulate. The pvalue of the Fstatistics tests considered significant was p < 0.05.
To perform the cluster ana lysis and to con struct the correspondence plots, Structure 2.3.3 (Stanford University, CA, USA) and Distruct 1.1 (Stanford University) were used, respec tively [27, 28] . For each run, 10,000 iterations after a burnin period of 10,000 iterations were utilized, and cluster coefficients (K) from 2 to 7 were considered.
To identify the most divergent geographic origin group in the functionalitybased haplo type ana lysis, we used the method proposed by Hofer and colleagues [29] . For each nonfunc tional haplotype i, we computed the average nonfunctional haplotype frequency p ij within each geographic origin group j, as well as the dif ference in the average frequency computed over all other populations via the following equation:
where p -ij is the average frequency of the non functional haplotype i in all populations not belonging to the geographic region j. To estimate the significance of nonfunctional haplotype frequency differences, we applied a test based future science group on 100,000 permutations, and we considered pvalues <0.05 significant.
Results
The firststage ana lysis was based on human genetic variation of 1249 SNPs that were located in 57 pharmacogenes (Supplementary table 2) . In order to graphically display the genetic variability of these loci among human populations, a cluster ana lysis was performed; Figure 1 shows the related plot. In regards to the geographical origin, differ ences were present among the considered popula tions. The largest difference was present between African and nonAfrican populations ( Figure 3 shows the molecular vari ance among the geographic groups that results from haplotypic analyses of molecular variance, and the number of the investigated SNPs for each geographicdifferentiated pharmacogene. This ana lysis proved that some pharmacogenes have a greater variance among geographic groups than what is considered average for the human genome (i.e., ~10%). However, this investigation does not take into account the functional impact of genetic variation and the role of rare variants in determining phenotype expression. To analyze the functional effect of all 55,521 variants and their combined effect on haplotype function, a previously described method was applied [20] . Supplementary tableS 3-64 report the results of the functional prediction ana lysis of the single vari ants and of the haplotypes. Considering the non functional haplotypes, a wide array of haplotype frequency differences among geographic groups were investigated. Figure 4 reports the distribu tion of haplotype frequency differences among the four geographic groups. This ana lysis sug gested that some pharmacogenes have geographic differences in nonfunctional haplotype frequen cies. The greatest difference was observed in the comparison between African and nonAfrican populations, but large differentiations were also observed in the comparisons of Europeans and Asians. To verify the statistical significance of these differences, a permutation test was applied. table 2 reports the pharmacogenes with signifi cant geographic differences in nonfunctional haplotype frequencies. Considering extreme non functional haplotype frequency differences In order to identify interactions between these significant functional geographic differ ences, we performed an ana lysis of databases of protein-protein interactions and molecular pathways (Supplementary table 65) . In hyper tension pharmacogenes functionally differentiated in African populations (i.e., ABCB1, ACE, ADRBK1, LPL, PPARA and TNFRSF11B), we recorded the same involvement of ABCB1 and LPL in the statin pathway (PharmGKB data base; Stanford University). In Asiandifferen tiated pharmacogenes (i.e., ADRA1A, APOB, CACNB2, CYP2C8, LIPC, LYZ and PPARA), our PharmGKB ana lysis highlighted the involve ment of APOB, CYP2C8 and LIPC in the statin pathway, and a STRING investigation con firmed the protein-protein interaction between LIPC and APOB. In Europeans, no potential inter actions among geographicdifferentiated pharmacogenes (i.e., ACE, ADRA1A, ADRBK1, CASR, LIPC and TNFRSF11B) were observed. discussion An investigation of human genomic variation, coupled with a functional prediction ana lysis, could help bring hypertension care into the 'personalized medicine' era. The present study provided an ana lysis of functional differences in hypertension pharmacogenes among human populations, and sought to understand the mechanisms of interpopulation differences in antihypertensive drug response and to obtain insights into interindividual variability.
The study was divided into two stages. In the first stage, ana lysis was focused on genetic variability among a large number of human populations (HGDP data: 51 populations). In the second stage, the aim was to investigate a large number of genetic variants (data from 1000 Genomes Project: 55,521 variants). The outcomes of the firststage ana lysis illu minated significant interpopulation differences. Conducting a cluster ana lysis led us to conclude that the main differences were present between Africans and nonAfricans. These results are in accordance with the great diversity of African genomes among human geographic groups and are likely owing to the African origin of humans [30, 31] . An ana lysis of Fstatistics showed that 116 of the 1249 SNPs significantly diverged among the investigated populations, suggesting that the pharmacogenes, in which these variants are located, may be functionally different among geographic groups.
The secondstage ana lysis highlighted that functional geographic differences are present in hypertension pharmacogenes and, in some cases, these diversities are significant. Extreme differences were observed between Africans and nonAfricans, in accordance with the firststage ana lysis, suggesting that these geographic func tional diversities are associated with differences in response to related antihypertensive drugs. However, significant functional differences are also present in European and Asian comparisons.
These findings are in agreement with previous studies that associated functional genetic differ ences with diversity in healthrelated aspects of human populations [19] . Considering each antihy pertensive drug separately, we were able to relate the genetic mechanisms according to the geo graphic differences of their anti hypertensive drug response. Atenolol is the most repeatedly used antihypertensive drug among our identified geo graphicdifferentiated pharmaco genes: ADRBK1 (Africa, Europe), LPL (Africa), PPARA (Africa, Asia), TNFRSF11B (Africa, Europe), APOB (Asia), ADRA1A (Asia, Europe), CACNB2 (Asia), LIPC (Europe) and CASR (Europe). An ancestry based study conducted on atenolol response made it clear that hypertensive patients with African ori gins are less responsive to atenolol monotherapy than patients with European origins [32] . Further more, a pharmacometabolomic study confirmed geographic differences in response to atenolol treatment, suggesting that dissimilar metabolo mic signatures of atenolol exposure are present between African and European hypertensive patients [33] . The second antihypertensive drug associated with our geographicdifferentiated future science group pharmacogenes is irbesartan (an angiotensin receptor blocker): LPL (Africa), PPARA (Africa, Asia), TNFRSF11B (Africa, Europe), APOB (Asia), ADRA1A (Asia, Europe), LIPC (Europe) and CASR (Europe). All irbesartanrelated phar macogenes are also involved in atenolol response. Geographic studies on irbesartan determined that monotherapy is less efficacious in patients with African origins than in patients with European origins [34] . The ACE inhibitorrelated pharma cogenes that are analyzed in the present study are involved in lisinopril response: our data suggested that the ACE gene is differentiated in African (nonfunctional haplotype frequency: 90.7%) and European populations (nonfunctional haplotype frequency: 46.0%). Few data are available regard ing geographic differences in ACEinhibitor response. However, it has been demonstrated that African patients have a higher risk of angioedema and cough due to ACEinhibitor treatment than European ones [35] . Our data regarding func tional pharmacogenetic diversity among human populations seem to be in accordance with the epidemiological data gathered on interpopulation variability in the responsiveness of ACE inhibitors and bblockers [32] [33] [34] [35] ; with similar geographic differentiated pharmacogenes corresponding to similar geographicdifferentiated drug responses.
Regarding calcium channel blockers, two phar macogenes displayed results that were geographi cally differentiated: ABCB1 (Africa) and CYP2C8 (Asia). Epidemiological data about geographic variability in calcium channel blockers high lighted that these drugs reduce blood pressure across all patient groups, regardless of sex, geo graphic origin, age and dietary sodium intake [36] . Therefore, we hypothesized that functional differences observed in ABCB1 and CYP2C8 may be attributed to other functionhomolog genes. Finally, the LYZ gene is the only geographically differentiated pharmacogene involved in the response of hydrochlorothiazide that showed a higher frequency of nonfunctional haplotypes in Asian populations (74.7%) than in nonAsian ones (Africa: 48.3%; America: 57.4%; Europe: 51.1%). Ancestrybased studies conducted on hydrochlorothiazide response have suggested that geographic origin plays a role in determining side effects related to this antihypertensive therapy [37] . However, little information is available about the geographic differences of hydrochlorothia zide response in Asian populations with respect to other geographic groups.
An investigation of protein-protein inter action and samepathway involvement among geographically differentiated pharmacogenes [43] Atenolol b-blocker [43] PPARA 0.574 (0.003) Irbesartan, telmisartan Angiotensin receptor blocker [43, 44] Atenolol b-blocker [43] ACE 0.343 (0.003) Lisinopril ACE inhibitor [45] ABCB1 0.363 (0.002) Bepridil, diltiazem, mibefradil, verapamil
Calcium channel blocker [46, 47] TNFRSF11B 0.311 (0.014) Irbesartan Angiotensin receptor blocker [43] Atenolol b-blocker [43] Asia LYZ 0.224 (0.003) Hydrochlorothiazide Diuretics [48] PPARA -0.368 (0.007) Irbesartan, telmisartan Angiotensin receptor blocker [43, 44] Atenolol b-blocker [43] APOB 0.157 (0.010) Irbesartan Angiotensin receptor blocker [43] Atenolol b-blocker [43] ADRA1A 0.296 (0.007) Irbesartan Angiotensin receptor blocker [43] Atenolol b-blocker [43] CACNB2 0.265 (0.003) Atenolol b-blocker [49] LIPC 0.296 (0.003) Irbesartan Angiotensin receptor blocker [43] Atenolol b-blocker [43] CYP2C8 -0.162 (0.015) Verapamil Calcium channel blocker [50] Europe ADRBK1 0.379 (0.020) Atenolol b-blocker [42] CASR 0.198 (0.020) Irbesartan Angiotensin receptor blocker [43] Atenolol b-blocker [43] ADRA1A -0.278 (0.020) Irbesartan ACE inhibitor [43] Atenolol b-blocker [43] ACE -0.252 (0.020) Lisinopril ACE inhibitor [45] LIPC -0.240 (0.020) Irbesartan Angiotensin receptor blocker [43] Atenolol b-blocker [43] TNFRSF11B -0.234 (0.040) Irbesartan Angiotensin receptor blocker [43] Atenolol b-blocker [43] DF: Nonfunctional haplotype frequency differences.
future science group factor for cardiovascular diseases and statins are the firstchoice drugs for lowdensity lipo proteincholesterol reduction [38] . According to our genetic data, despite the fact that statins seem to reduce the cardiovascular events in different geographic groups, significant differ ences in the reduction of lowdensity lipopro tein levels and in the adverse rates were never theless present in treated individuals, especially in patients with European ancestry and African ancestry [39] .
Considering the comparison between our genetic data and epidemiological information collected on antihypertensive drug response, a concordance seems to be present. However, geographic studies on drug response are mainly carried out in the USA or in other countries in which different geographic groups are pres ent within their populations. Therefore, little information has been gathered about some human populations: for instance Middle Eastern or east Asian populations. However, our data highlighted different hypotheses to explain geographic differences in antihyper tensive drug response. In particular, our data on rare variants highlighted that the pharma cogenetics of hypertension is strongly affected by personal genetic variation and common variants account for only a small percentage of functional interindividual differences in hypertension pharmaco genes. This result is in agreement with the current body of knowledge relating to human genetics, and it supports the idea that complex phenotypes can be attrib uted mainly to rare variants [11, 40] . Moreover, recently Nelson and colleagues indicated that an abundance of rare functional variants is present in drug target genes [41] . Therefore, pharmacogenomic research should be based on NGS technologies as this could analyze the effect of individual genetic variation on drug response and bring pharmacogenomics into the 'personalized medicine' era, as suggested by recent papers [12, 15] . Although NGS ana lysis may open up new scenarios in pharmacoge nomics, the economic costs are still higher than the gene candidate or genomewide association study approaches. The functional prediction ana lysis we performed on NGS data may pro vide the basis to design a SNP array that could analyze the role of functional rare and com mon variants in hyper tension pharmacogenes. In this way, an explorative study, which would be less expensive than an NGS ana lysis, could be performed to analyze the impact of rare variants in hypertension pharmacogenomics. This kind of investigation may be a determi nant in developing a reliable pharmacogenomic test that could be used to select the optimal antihypertensive therapy for each patient.
Conclusion
Our study provided relevant information on the interpopulation differences in hyper tension pharmacogenes, highlighting geographically differentiated mechanisms that affect their responses to antihypertensive drugs. How ever, although a number of studies have been performed providing data on hypertension pharmaco genomics, the relationship between genes and antihypertensive drugs is not cur rently completely understood. Therefore, our outcomes, based on the current knowledge of hypertension pharmacogenomics, must be confirmed and deepened by further studies. Indeed, one of the most important results of our study was the main role of rare variants in determining the functionality of hypertension pharmacogenes. This indicates that investiga tions based on NGS technologies are necessary to completely understand hypertension pharma cogenomics and to produce important essential and economic improvements.
Future perspective
In the coming years, the use of highthrough put technologies in clinical practice will allow us to improve our capacity to personalize the healthcare of each individual. Regarding hypertension drugs, the application of NGS technology, together with other research fields (e.g., proteomics and metabolomics), may allow the translation of pharmacogenetic knowledge from scientific literature to clinical routine.
executive summary

Background
The ana lysis of interpopulation genetic differences is a useful method to investigate the predisposition to health-related phenotypes.
A number of studies highlighted that human populations with different geographic origins have a different response to antihypertensive drugs. Currently, pharmacogenetic studies on antihypertensive drugs have provided few useful data to identify the optimal therapy for each patient.
Results
Our study provided new data about the functional variation of hypertension pharmacogenes among human populations. This genetic outcome seems to be in accordance with the epidemiological information on the geographic variation of antihypertensive drug response. Moreover, the present ana lysis indicated that rare variants have a higher impact in determining the function of hypertension pharmacogenes with respect to common ones.
Conclusion
Based on the present results, we provide new insights into the potential mechanisms of antihypertensive drug response.
Further studies based on next-generation sequencing technologies may result in the development of reliable pharmacogenetic tests for antihypertensive drugs. 
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